Senju Pharmaceutical Co., Ltd.

Other

Mitsubishi Tanabe Pharma Corporation

Astellas Pharma Gmbh

Tohoku University

Mitsuyoshi Azuma

Jun Inoue

Takeshi Nakajima

Yukuo Yoshida

Yuka Yoshida

Chiho Fukiage

Masayuki Nakamura

Yuji Sakamoto

Masayoshi Uehata

Mitsunori Waki

Yoshikuni Nakamura

Yoshiko Takayama

Fumiko Yano

Yujiro Yamamoto

Hiroshi Kuriyama

Chiho Yabuta

Tomoko Nakajima

Emi Nakajima

Ying-She Cui

Ayumi Nakagawa

Takashi Toyama

Yoshiro Saito

Noriyasu Hirasawa

Yayoi Kishimoto

A therapeutic agent for a corneal epithelial disorder, containing a miR-203 inhibitor; an agent for promoting proliferation of corneal epithelial cells, containing a miR-203 inhibitor; a liquid culture medium for use in the manufacture of a corneal epithelial sheet, containing a miR-203 inhibitor; and a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using a liquid culture medium containing a miR-203 inhibitor. According to the present invention, a therapeutic agent for a corneal epithelial disorder, an agent for promoting proliferation of corneal epithelial cells, a liquid culture medium for use in the manufacture of a corneal epithelial sheet, a method for producing a corneal epithelial sheet, including the step of culturing corneal epithelial cells using the liquid culture medium, and a method for treating a corneal epithelial disorder can be provided. The present inventors have also found that not only the above effects are exhibited by inhibiting miRNA richly contained in tears, but also the agent specifically acts on eye surfaces, so that the present invention can be expected to show high safety.

Therapeutic agent for corneal epithelial disorder

The invention provides an agent for promoting ocular tissue neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof, and an agent for promoting corneal neuritogenesis and retinal neuritogenesis, containing N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide or a pharmaceutically acceptable salt thereof. The corneal neuritogenesis promoter can be used for the improvement of corneal sensitivity, treatment of dry eye, or treatment of a corneal epithelial disorder. The retinal neuritogenesis promoter can be used for the improvement of a visual dysfunction.

Neurite formation promoter

The invention provides a polypeptide containing an amino acid sequence, which is a particular partial sequence of lacritin and is characterized by gyro-modification of N-terminal glutamine. The polypeptide promotes adhesion between a cell and extracellular matrix and is stable in aqueous solution.

Partial peptide of lacritin

The invention provides a polypeptide comprising the amino acid sequence of SEQ ID NO: 1, which is a particular partial sequence of lacritin, and having an amino acid length of not more than 70 residues. The polypeptide of the invention can promote adhesion between a cell and an extracellular matrix, and can promote tear fluid secretion from lacrimal gland acinar cells.

Provided is a pharmaceutical product exhibiting a high therapeutic effect in the treatment of retinal diseases associated with angiogenesis such as age-related macular degeneration, diabetic retinopathy and the like. A therapeutic agent for a retinal disease, containing a substance specifically inhibiting HIF-1&#x3b1; expression and a substance specifically inhibiting HIF-2&#x3b1; expression. The aforementioned inhibitory substances, which are active ingredients in the therapeutic agent of the present invention, are nucleic acids capable of inducing RNAi, antisense nucleic acids or ribozymes for HIF-1&#x3b1; and HIF-2&#x3b1;, or expression vectors thereof.

Pharmaceutical containing HIF-1 alpha and HIF-2 alpha expression inhibitor

The amide compound of the formula (I) [each symbol is as defined in the description] has a promoting action on neuritogenesis of trigeminal nerve cells, and the compound is useful as a corneal neuritogenesis promoter, an agent for recovering corneal sensitivity by promotion of corneal neuritogenesis, and an agent for treating dry eye. 

Agent for repairing corneal sensitivity containing amide compound

Corneal perception recovery drug containing amide compound

Preventives/remedies for glaucoma

Agent for prophylaxis and treatment of glaucoma

A calpain protein which is specific for the retina in eye tissues containing a protein having an amino acid sequence represented by SEQ ID NO: 1 in Sequence Listing; a DNA represented by SEQ ID NO: 2 in Sequence Listing which encodes the above protein; a vector containing this DNA; a transformant transformed by this vector; and a process for producing the calpain protein which comprises culturing the transformant.

Calpain and DNA encoding the same

Angiogenesis inhibitor

A pharmaceutical composition for the prophylaxis and therapy of a disease arising from ocular fundus tissue cytopathy such as retinochoroidal disease, glaucoma, and posterior complication arising form photocoagulation, which contains, as an active ingredient, a compound of formula (I) wherein R represents an alkyl group having 1 to 4 carbon atoms or an aryl group having 6 to 10 carbon atoms which is optionally substituted; R and R may be the same or different and each represents hydrogen or an alkyl group having 1 to 4 carbon atoms or R and R may jointly form a ring having 3 to 7 carbon atoms; and R represents a lower alkyl group which substituted by aryl, cycloalkyl, or aromatic heterocyclic residue, or a pharmaceutically acceptable salt thereof.

Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytography

Pharmaceutical composition containing a cysteine protease inhibitor for prophylaxis and therapy of brain tissue impairment

An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I)

An angiogenesis inhibitor comprising a cysteine protease inhibitory compound. As the preferable cysteine protease inhibitory compound, epoxysuccinic acid compounds, peptide halohydrazide compounds, calpain inhibitory compounds, compounds of the formula (I) ##STR1## and compounds of the formula (VI) ##STR2## can be used. The angiogenesis inhibitor of the present invention suppresses new formation of blood vessels in the living tissues, so that it can be used as a superior therapeutic or prophylactic agent of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; and angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, senile discoid macular degeneration and the like, as well as for prevention of metastasis of tumors.

Growing community of inventors

Nishinomiya, Japan

Mitsuyoshi Azuma